Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443578 | 0.84 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL4103602 | 0.75 | TSHR (0.53) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL29620231 | 0.75 | TSHR (0.53) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL29620230 | 0.75 | TSHR (0.53) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL95210 | 0.75 | TSHR (0.42) | MEN1KMT2AALDH1A1TSHRCYP1A2 | |
| SCHEMBL7680857 | 0.74 | CYP1A2 (0.40) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL21178072 | 0.74 | MEN1 (0.37) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL9099943 | 0.74 | KMT2A (0.45) | MEN1KMT2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL97421 | 0.74 | — | — | |
| SCHEMBL102469 | 0.73 | CYP1A2 (0.36) | MEN1KMT2AALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022006498-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2021-02-11 | — | — | US | disclosed |
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | MEN1 4626/4885KMT2A 539/4885ALDH1A1 3300/4885 |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | CNR1, CNR2, CD74 | MEN1 2935/4885KMT2A 3148/4885ALDH1A1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.